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A prospective study comparing
whole-body skeletal X-ray survey with
18F-FDG-PET/CT, 18F-NaF-PET/CT and
whole-body MRI in the detection of bone
lesions in multiple myeloma patients
Eva Dyrberg1,2, Helle W. Hendel2, Gina Al-Farra1,
Lone Balding1, Vibeke B. Løgager1, Claus Madsen2 and
Henrik S. Thomsen1
Abstract
Background: For decades, the most widely used imaging technique for myeloma bone lesions has been a whole-body
skeletal X-ray survey (WBXR), but newer promising imaging techniques are evolving.
Purpose: To compare WBXR with the advanced imaging techniques 18F-fluorodeoxyglucose (FDG) positron emission
tomography (PET)/computed tomography (CT), 18F-sodium fluoride (NaF) PET/CTand whole-body magnetic resonance
imaging (WB-MRI) in the detection of myeloma bone lesions.
Material and Methods: Fourteen patients with newly diagnosed multiple myeloma were prospectively enrolled.
In addition to WBXR, all patients underwent FDG-PET/CT, NaF-PET/CT, and WB-MRI. Experienced specialists per-
formed blinded readings based on predefined anatomical regions and diagnostic criteria.
Results: In a region-based analysis, a two-sided ANOVA test showed that the extent of detected skeletal disease
depends on the scanning technique (P< 0.0001). Tukey’s multiple comparison test revealed that WB-MRI on average
detects significantly more affected regions than WBXR (P< 0.005), FDG-PET/CT (P< 0.0001), and NaF-PET/CT
(P< 0.05). In a patient-based analysis, a Cochran’s Q test showed that there are no significant differences in the pro-
portion of patients with bone disease detected by the different scanning techniques (P¼ 0.23). Determination of
intrareader variability resulted in Kappa coefficients corresponding to moderate (FDG-PET/CT) and substantial agree-
ment (WB-MRI, WBXR, NaF-PET/CT).
Conclusion: WB-MRI detects on average significantly more body regions indicative of myeloma bone disease compared
to WBXR, FDG-PET/CT, and NaF-PET/CT. The lack of significance in the patient-based analysis is most likely due to the
small number of study participants.
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Introduction
The vast majority of myeloma patients develop bone
lesions during their course of disease. Myeloma bone
lesions are a major cause of morbidity and mortality,
and complications include pathologic fractures, severe
bone pain, and spinal cord compression. The presence
of myeloma bone lesions has signiﬁcant impact on
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treatment strategy and the patients’ performance status
and survival (1,2).
A systematic review based on 32 studies compared
modern imaging techniques with whole-body skeletal
X-ray survey (WBXR) (3). The newer imaging methods
included magnetic resonance imaging (MRI), com-
puted tomography (CT), 18F-ﬂuorodeoxyglucose-
positron emission tomography (FDG-PET), and
FDG-PET combined with CT (FDG-PET/CT). The
newer imaging methods detected up to 80% more mye-
loma bone lesions than WBXR. In only four out of the
22 studies that included MRI examinations was MRI
performed as a whole-body scan (WB-MRI). None of
the included studies investigated the diagnostic value of
18F-sodium ﬂuoride (NaF) PET/CT, reﬂecting the
sparse literature on NaF-PET/CT application in mye-
loma patients.
Therefore, we undertook a comparative study of
WBXR vs. FDG-PET/CT, NaF-PET/CT, and WB-
MRI in the detection of bone lesions in newly diag-
nosed myeloma patients.
Material and Methods
Participants
The study protocol was approved by the regional ethics
committee (approval number H-3-2012-022), and the
study participants were prospectively enrolled in the
period from October 2012 to August 2015. Written
informed consent was obtained from all participants.
The study population consisted of 14 patients (seven
women, seven men; mean age¼ 68 years; age
range¼ 53–87 years) with newly diagnosed multiple
myeloma diagnosed according to standard criteria (4).
One additional patient was recruited, but could not
complete the MRI scanning and was excluded, as the
patient decided not to undergo further project scans.
Exclusion criteria were: bone metabolism disorder;
other malignancy within the last ten years; claustropho-
bia; overweight exceeding the scanning capacity
(>195 kg); allergy to iodinated contrast media; esti-
mated glomerular ﬁltration rate< 45mL/min; and
contraindications for MRI. The project scans were per-
formed in random order, within an average of 14 days
(range¼ 3–33 days) from the WBXR.
All imaging was performed before initiation of any
chemotherapy. Some patients (5/14) had initiated ster-
oid within 20 days of imaging.
WBXR data acquisition
WBXR was performed using a standard X-ray unit
(DX Digital Diagnost 2.1.4 2012, Philips Healthcare,
Best, The Netherlands). The WBXR comprised
18 conventional radiographs of the entire skeleton:
skull (two planes); cervical/thoracic/lumbar spine (two
planes); chest; pelvis; upper arms; thigh bones; fore-
arms; and lower legs.
Total acquisition time was approximately 40min
and the average radiation dose was approximately
1mSv.
18F-FDG-PET/CT data acquisition
The patients were fasting 5 h before the intravenous
tracer injection; the scanning (Either Gemini TF,
Philips Healthcare, Best, The Netherlands or
Biograph mCT 64 S, Siemens Healthcare, Munich,
Germany based on availability) was performed
1 h 10min post injection. The average 18F-FDG
dosage was 353MBq (range¼ 213–400MBq).
First the CT scan was obtained, then immediately
after the PET emission scan. The patients were pos-
itioned supine head-ﬁrst with arms above the head.
Images were obtained from the top of the skull to just
below the knees. Total scan time was 15–20min.
The ﬁrst three participants underwent a low-dose CT
scan. Due to a change in our CT protocol, the remain-
ing study participants underwent a diagnostic CT with
intravenous iodinated contrast. The total radiation
dose from the FDG-PET/CT scan was approximately
8mSv (performed with low-dose CT) and approxi-
mately 16mSv (performed with diagnostic CT).
One study participant did not show up for the FDG-
PET/CT scanning, but completed the other project
scans. Further technical details are given in Table 1.
18F-NaF-PET/CT data acquisition
The scanning (Either Gemini TF, Philips Healthcare or
Biograph mCT 64 S, Siemens Healthcare based on
availability) was performed 30 min after the intraven-
ous administration of 18F-NaF with an average dose of
200MBq (range¼ 198–213MBq) without any special
patient preparations beforehand. All CT scans were
performed as a low-dose CT.
Patients were positioned supine head-ﬁrst with arms
above the head. Images were obtained from the top of
the skull to just below the knees. The total scan time
was approximately 15min. The total radiation dose
from the NaF-PET/CT scan was approximately
8mSv. Further technical details are given in Table 1.
MRI data acquisition
WB-MRI was performed on either a whole-body 1.5-T
MRI Achieva with a Q-body coil (Philips Healthcare)
with a Q-body coil (participants 1–5) or a whole-body
3.0-T MRI (Ingenia; Philips Healthcare) with a
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dedicated phased array coil (participants 6–14) based
on availability. The examination protocol consisted of
coronal T1, STIR-weighted images, and axial diﬀusion-
weighted images (DWI) b1000. In addition, DWI b0
and sagittal T1 of the vertebral spine were obtained
in study participants 6–14.
The patients were positioned supine head-ﬁrst with
arms along the body. The isocenter of the magnet was
focused on the forehead. Images were obtained from
the top of the skull to the feet. The total scan time
was approximately 1 h. Further technical details can
be found in Tables 2 and 3.
Image evaluation
Experienced specialists in the ﬁeld of radiology and
nuclear medicine interpreted the images. The primary
readings were performed after the inclusion of the last
participant and within a short period of time.
Secondary readings were later performed to determine
intra reader variability.
Each reader performed the evaluations blinded to
other imaging results as well as to the patient’s clinical
condition. The reader assessed whether myeloma indi-
cative bone lesions were present in eight predeﬁned
Table 1. PET/CT examination protocols.
Scanner
Philips Gemini
TF 16 slices
Siemens Biograph
mCT64 64 slices
PET
FDG-PET
Bed positions (n) 8 6
Time per bed position (min) 2 2
NaF-PET
Bed positions (n) 15 10
Time per bed position (min) 1 1
FOV (mm) 180 210
Overlap (mm) 90 40
Matrix size 144 144 400 400
Pixel size (mm) 4 2.04
Reconstruction BLOB-OS-TF TrueXþTOF 4i21s
CT
CT low-dose:
Tube voltage product (kV) 140* 120*
Tube current time product (mAs) 20* 40*
CT diagnostic:
Tube voltage product (kV) 120* 120*
Tube current time product (mAs) 250* 200*
Matrix size 512 512 512 512
Pixel size (mm) 1.17 0.91
Field of view (mm) 500 500
Reconstructed slice (mm) 3 3
Thickness increment (mm) 1.5 3
*Reference dose CareDose4D.
Table 2. MRI examination protocol. 1.5T Philips Achieva,
Q-body coil.
Coronal
STIR
Coronal
T1
Axial DWI
b¼ 1000 s/mm2
Pulse sequence IR TSE DWIBS
Repetition time (ms) 2444 537 3089
Echo time (ms) 64 18 65
Flip angle () 90 90 90
Field of view (mm) 530 209 530 209 530 216
Acquisition matrix 336 120 208 287 108 43
Slices (n) 30 30 44
Thickness (mm) 6 6 6
IR, inversion recovery; TSE, turbo spin echo; DWIBS, diffusion-weighted
whole-body imaging with body background signal suppression.
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skeletal body regions covered by all scanning tech-
niques: (i) skull; (ii) ribs; (iii) pelvis; (iv) cervical
spine; (v) thoracic spine; (vi) lumbar spine; (vii) long
bones (upper arms and thighs); and (viii) other regions
(shoulder blades, breast bone, collar bones).
As in a previous study by Narquin et al. (5), the
radiographic evaluation was based on the Lodwick
classiﬁcation system of bone destruction. We con-
sidered Lodwick classiﬁcation type 1b/1c (punch-out
lesion with distinct/indistinct border), 2 (moth-eaten
pattern), and 3 (permeative pattern) indicative of osteo-
lytic myelomatous bone disease (6).
The MRI evaluation was based on the combined
ﬁndings on T1-weighted (T1W) images, STIR-weighted
images, and DWI as described in Bone Marrow MRI by
Moulopoulos and Koutoulidis, with the typical pattern
of focal myeloma lesions being hypointense on T1,
hyperintense on STIR, and with high intensity on
DWI (7). The PET/CT scans were initially analyzed
according to criteria described by Mesguich et al. (8).
However, the most recent imaging criteria from the
International Myeloma Working Group (IMWG)
state that PET uptake alone is not adequate to diagnose
a myeloma bone lesion and that a correlated CT ﬁnding
of an osteolytic bone destruction is required (4).
Therefore, we modiﬁed the primary FDG-PET/CT
analysis to the new criteria as this was possible due to
separate recording of the FDG-PET and CT ﬁndings.
A parallel modiﬁcation was possible with the secondary
NaF-PET/CT reading only, and for that reason this
analysis was included in the statistical analyses.
Statistical analysis
A Cochran’s Q test was performed for a patient-based
analysis, testing whether there are diﬀerences in the
proportion of patients detected with bone disease by
each scanning technique. The patient with the missing
FDG-PET/CT was excluded from the Cochran’s
Q-test, as the test cannot handle a missing observation.
A two-sided ANOVA test was performed for a
region-based analysis, testing whether there are diﬀer-
ences between the average numbers of aﬀected regions
detected by each scanning technique. Subsequently,
Tukey’s multiple comparison test was conducted to
test for pairwise diﬀerences. The missing FDG-PET/
CT scan was taken into account in both tests.
The null hypothesis for the tests was that there are
no diﬀerences in the outcomes of the scanning tech-
niques. A P value< 0.05 was considered the level of
signiﬁcance.
Intrareader variability was determined calculating
Kappa coeﬃcients. The analyses were performed
using the statistical software package ‘‘R’’.
Results
The scanning technique that diagnosed the largest pro-
portion of the patients with myeloma bone disease was
WB-MRI (Table 4). However, a Cochran’s Q test
showed that there were no signiﬁcant diﬀerences in
the proportion of patients with bone disease detected
by the four scanning techniques (P¼ 0.23).
Table 5 depicts for each scanning modality the
number of detected regions with bone disease per
patient. A two-sided ANOVA test showed that the
extent of bone disease depends on the scanning tech-
nique (P< 0.0001). Compared to the WBXR, FDG-
PET/CT detects on average one less aﬀected region
per patient, whereas NaF-PET/CT detects on average
0.6 more aﬀected regions and WB-MRI 2.6 more.
Tukey’s multiple comparison test showed that WB-
MRI on average detects signiﬁcantly more aﬀected
regions compared to WBXR (P< 0.005), FDG-PET/
CT (P< 0.0001), and NaF-PET/CT (P< 0.05). All
other pairwise comparisons were non-signiﬁcant.
Table 3. MRI examination protocol. 3.0T Philips Ingenia, dedicated phased array coil.
Coronal STIR Coronal T1
Sagittal T1
columna totalis
Axial DWI
b¼ 0, 1000 s/mm2
Pulse sequence IR TSE TSE DWIBS
Repetition time (ms) 7794 500 428 9371
Echo time (ms) 71 6.4 16 65
Flip angle () 90 90 90 90
Field of view (mm) 470 287 480 279 450 210 550 319
Acquisition matrix 312 187 320 216 298 168 124 63
Slices (n) 36 35 11 55
Thickness (mm) 7 7 5 5
IR, inversion recovery; TSE, turbo spin echo; DWIBS, diffusion-weighted whole-body imaging with body background signal
suppression.
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With regard to the anatomical distribution of the
aﬀected regions, WB-MRI outscored the other imaging
techniques in all anatomical areas except in the skull,
where WBXR detects myeloma disease in the largest
proportion of patients (Table 6).
No extramedullary myeloma disease (EMD) was
detected in any of the patients.
Determination of intrareader variability resulted in
Kappa coeﬃcients corresponding to moderate (FDG-
PET/CT) and substantial agreement (WB-MRI,
WBXR, NaF-PET/CT) in both the patient and region
level analyses (Table 7).
Discussion
Accurate detection of myeloma bone lesions is crucial
for treatment planning and patient prognosis, and
increasingly important with the development of new
treatment strategies.
At WBXR, an X-ray beam is projected through the
body and absorbed in varying degrees in the diﬀerent
tissues, thereby allowing an image to be detected.
Myeloma bone lesions typically appear as well-deﬁned
small ‘‘punched-out’’ lesions, representing bone
destruction and replacement of marrow cells with
plasma cells (Fig. 1a) (9). However, the use of WBXR
can result in an underestimation of the extent of bone
disease, since typically 70% or more of the bone tissue
needs to be destroyed before a focal osteolytic lesion
becomes apparent (2).
In PET/CT imaging, a radioactive tracer is adminis-
tered intravenously. Subsequently, the PET camera
detects tissues with increased tracer uptake and the
CT component allows precise anatomical localization
of these areas. The most widely used PET tracer FDG
accumulates in metabolically active cells with high glu-
cose demand, including malignant cells (Fig. 1b). The
PET tracer NaF is bone-speciﬁc and accumulates in
bones reﬂecting bone modelling and regional blood
ﬂow. In osteolytic bone lesions, NaF accumulates in
Table 4. Proportion of patients with bone disease per modality.
WBXR NaF-PET/CT FDG-PET/CT WB-MRI
Proportion of patients with bone disease:
Cohrans’s Q test:
P¼ 0.23
8/14 10/14 6/13* 11/14
*One patient did not have a FDG-PET/CT scan performed.
Table 5. Number of affected regions per patient per modality.
Patient no. WBXR NaF-PET/CT FDG-PET/CT WB-MRI
1 3 0 1 7
2 0 0 0 6
3 2 3 0 4
4 8 8 NA* 7
5 0 2 0 7
6 3 6 0 8
7 3 4 1 7
8 3 3 1 0
9 5 8 2 8
10 0 1 0 0
11 6 5 4 8
12 0 0 0 0
13 0 0 0 1
14 0 1 4 6
Total 33 41 13 69
Two-sided ANOVA
(P< 0.0001)
Effect estimates:
0 0.57 –1.03 2.57
Patients 1, 4, 8, 9, and 11 initiated steroid treatment within 20 days of
imaging.
*One patient did not have a FDG-PET/CT scan performed.
Table 6. Anatomical distribution of the total number of
affected regions per imaging technique.
WBXR
NaF-
PET/CT
FDG-
PET/CT WB-MRI
Patients (n) 14 14 13* 14
Anatomical regions:
Cervical spine 3 3 0 9
Thoracic spine 1 6 3 10
Lumbar spine 3 6 0 10
Skull 8 3 0 4
Pelvis 5 6 1 10
Ribs 2 8 4 10
Long bones: upper
arms and thighs
7 5 4 8
Other: shoulder
blades, breast bone,
collar bones
4 4 1 8
Total 33 41 13 69
*One patient did not have a FDG-PET/CT scan performed.
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the rim of the lesions corresponding to osteoblast activ-
ity (Fig. 1c) (10–12).
MRI is based on radio waves and magnetic ﬁelds
and is, as opposed to WBXR and PET/CT, radiation-
free. Advances in the MRI technology have enabled
the acquisition of WB-MRI images and DWI.
Conventional MRI images can detect replacement of
the normal bone marrow by tumor cells regardless of
the degree of bone destruction (7). DWI provides func-
tional information based on the fact that tumor tissue
has limited diﬀusion of water and appears as high
signal-intensity regions (Fig. 1d–g) (13).
The diﬀerences in the physical and technical prin-
ciples behind the imaging modalities can explain the
discrepancy in their diagnostic performances. Fig. 2
shows a myeloma lesion in the body of C7 detected
on WB-MRI only.
The lack of an ideal reference standard is a limita-
tion in diagnostic studies. Ideally, biopsies of all
suspected myeloma bone lesions (and theoretically of
non-involved bone too) should be performed to histo-
logically conﬁrm the image ﬁndings. However, this was
neither practically nor ethically possible. In this study,
all image ﬁndings are considered indicative of myeloma
Table 7. Intrareader variability.
Imaging method Patient no. Patient level analysis Region level analysis
Kappa coefficients (95% CI) Kappa coefficients (95% CI)
WB-MRI 14 0.76 (0.30–1.00) 0.64 (0.49–0.78)
FDG-PET/CT 13 0.55 (0.11–1.00) 0.44 (0.21–0.66)
NaF-PET/CT* 14 0.66 (0.22–1.00) 0.66 (0.52–0.80)
WBXR 14 0.72 (0.36–1.00) 0.78 (0.65–0.91)
*Calculation is based on image reading criteria described by Mesguich et al. (8).
Fig. 1. A 71-year-old man with newly diagnosed multiple myeloma. A lesion in the glenoid cavity of scapula bone is detected by all four
imaging techniques (arrows). (a) Whole-body X-ray: a ‘‘punched-out’’ lesion. (b) FDG-PET/CT: accumulation of FDG representing the
lesion. (c) NaF-PET/CT: accumulation of NaF in the rim of the lesion. (d–g) Whole-body 3T MRI: the lesion is detected on all four MRI
sequences: (d) hyperintense on coronal STIR, (e) hypointense on coronal T1W imaging, (f) high signal intensity on axial DWI b1000,
and (g) low signal intensity on axial ADC. ADC value is 1.05 10–3 mm2/s (SD¼ 0.11).
Fig. 2. A 61-year-old woman with newly diagnosed multiple myeloma. A lesion in the body of C7 is detected on whole-body 3T MRI
only (arrows). No C7 lesion is detected on (a) whole-body X-ray, (b) FDG-PET/CT, or (c) NaF-PET/CT (circles). The C7 lesion is
detected on all four MRI sequences with findings indicative of a myeloma bone lesions (arrows): (d) hypointense on coronal T1W
imaging, (e) hyperintense on coronal STIR, (f) high signal intensity on DWI b1000, and (g) low signal intensity on axial ADC. ADC value
is 0.52 10–3 mm2/s (SD¼ 0.1).
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bone disease and detection rates are compared as in
previous studies (14–17).
This study shows that WB-MRI, on average, detects
signiﬁcantly more regions with myeloma bone disease
than WBXR, FDG-PET/CT, and NaF-PET/CT. The
sparsely investigated NaF-PET/CT is not superior, but
equivalent to WBXR. A comparison of the anatomical
distribution of the bone disease showed that WB-MRI
outscores the other imaging techniques in all regions
apart from the skull region, where WBXR detects the
largest proportion of patients with myeloma bone dis-
ease. This is in line with previous descriptions of
WBXR as being particularly sensitive in the skull and
the extremities and is explained by the lack of overlap-
ping structures in these regions (2).
The small number of included study participants
most likely caused the lack of signiﬁcance in the
patient-based analysis. The diﬃculties with the recruit-
ment of study participants were probably due to a low
disease incidence combined with a comprehensive pro-
ject-scanning regime.
The relatively long inclusion period had the conse-
quence that not all WB-MRI and PET/CT were
obtained on the exact same scanner and with the precise
same scanning protocol during the whole period.
However, all MRI scans were obtained as whole-body
scans, and the convincing MRI results in regard to
number of aﬀected regions per patient seem independ-
ent of the MRI scanner used. In addition, all FDG-
PET ﬁndings had correlated CT ﬁndings both when
low dose CT and diagnostic CT were performed, and
therefore the change of CT protocol did not inﬂuence
the FDG-PET/CT results. We therefore believe that
these minor technical diﬀerences did not inﬂuenced
the overall results.
Studies elucidating the value of NaF-PET/CT in
multiple myeloma patients are limited. The NaF-PET/
CT results in this study are not convincing and thereby
in line with other recently published prospective studies
(10,12). A challenge for NaF-PET/CT is that NaF
accumulates in the rim of the osteolytic lesions, which
can make the detection of smaller myeloma lesions dif-
ﬁcult. In addition, the NaF accumulation represents a
secondary osteoblastic reaction to the myeloma cells in
the bone marrow, and therefore might not be visible at
an early stage.
Five of the study participants had initiated steroid
therapy at the time of imaging (< 20 days). As known
from treatment monitoring studies in other diseases,
corticosteroids may result in decreased FDG uptake
representing decreased bone marrow activity after suc-
cessful treatment (18–20). Similarly, lower signal inten-
sities and higher ADC values have been observed after
steroid treatment on DWI MRI (21). In daily clinical
practice, however, myeloma patients have often
initiated steroid therapy at time of imaging due to
their clinical condition. Hence, this study reﬂects daily
clinical practice and the setting to which the results will
be applied. Future studies are needed to investigate the
inﬂuence of steroid on FDG-PET/CT and DWI MRI
in myeloma patients.
FDG PET/CT may lead to false-negative results in
the presence of skull lesions, due to physiologically high
FDG uptake in the brain. Both FDG-PET/CT and WB-
MRI can detect EMD. The identiﬁcation of EMD is
important, as it identiﬁes patients with an inferior prog-
nosis (2). However, no EMD was detected in this study.
In line with Regelink et al., we found that WB-MRI
outscored both WBXR and FDG-PET/CT, indicating
that WB-MRI is a valuable alternative as imaging tech-
nique in newly diagnosed myeloma patients (3). A deter-
mination of the intrareader variability in this study
resulted in Kappa coeﬃcients at the favorable end of
the scale underlining that the image analyses are reliable.
In conclusion, WB-MRI detects on average signiﬁ-
cantly more regions indicative of myeloma bone disease
compared to WBXR, FDG-PET/CT, and NaF-PET/
CT. The sparsely investigated NaF-PET/CT is not
superior, but equivalent to, the current standardWBXR.
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